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Background. The potential benefits of administering a dose of intravenous iron in patients with moderate postpartum anaemia
rather than oral iron alone remains unproven. Aims. To determine whether a single injection of intravenous iron followed by a 6-
week course of oral iron is as effective over 6months in restoring normal haemoglobin levels and replenishing iron stores in women
withmoderate postpartum anaemia as a course of oral iron alone in womenwithmild postpartum anaemia.Materials andMethods.
Retrospective two-arm cohort study in women with mild postpartum anaemia (haemoglobin 9.6–10.5 g/dL) prescribed iron daily
for 6 weeks (𝑁 = 150) and womenwithmoderate postpartum anaemia (haemoglobin 8.5–9.5 g/dL), given a single 500mg injection
of intravenous iron followed by iron daily for 6 weeks (𝑁 = 75). Haemoglobin and ferritin were measured 6 months postpartum.
Results. Haemoglobin returned to similar mean levels in both groups. Ferritin levels were statistically significantly higher in the
intravenous + oral group (57.7 ± 49.3 𝜇g/L versus 32.9 ± 20.1 𝜇g/L). Conclusions.Despite lower baseline haemoglobin, intravenous
iron carboxymaltose was superior to oral iron alone in replenishing iron stores in moderate postpartum anaemia and may prove
similarly beneficial in mild postpartum anaemia.
1. Introduction
Postpartum anaemia, defined by theWorld Health Organiza-
tion as a haemoglobin (Hb) level < 11.0 g/dL, is a very com-
mon obstetric problem usually resulting from a combination
of blood loss at delivery and preexisting iron deficiency [1]. Its
reported incidence 6 months postpartum ranges from 12.7%
to 30% [2–4]. Symptoms include lactation failure and post-
partum depression [3–5]. Stepwise interventions commonly
tailor treatment to the postpartum Hb level, using oral iron
for mild cases and intravenous iron for moderate to severe
cases, although cut-offs vary considerably [6, 7].
We earlier demonstrated the efficacy of oral iron in
postpartum iron deficiency without anaemia [8]. However,
several studies have since shown that intravenous therapy is
more effective than its oral counterpart for replenishing iron
stores in postpartum anaemia [9–12].
In the present retrospective study we postulated that
women treated with oral iron only for mild postpartum
anaemia would have lower ferritin levels at 6 months than
those treated with intravenous + oral iron for more severe
anaemia. Our aim was to compare efficacy at 6 months
between treating mild postpartum anaemia with oral iron
versus moderate anaemia with intravenous + oral iron under
the conditions of our institution’s stepwise management
schedule modelled on current best-practice recommenda-
tions [13].
2. Methods
The institution’s ethics committee approved the study proto-
col. Women were informed about the study by post around
5 months postpartum and all gave their informed consent
prior to participation. Data of patients were obtained from
the hospitals patients records.
Primary endpoints of the study were Hb and ferritin at
6 months postpartum (±28 days). The following parameters
were measured: whole blood count (flow cytometry: Advia
120, Bayer Health Care, Leverkusen, Germany), ferritin
(sandwich immunoassay: Automated Chemiluminescence
System 180, Chiron Diagnostics, East Walpole, MA, USA),
and C-reactive protein (CRP; turbidimetric immunoassay:
TinaQuant, Roche Diagnostics, Rotkreuz, Switzerland).
All women had been prescribed oral iron sulphate con-
taining 80mg elemental iron/day alone for 6 weeks after
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Table 1: Baseline data and characteristics.
Characteristics Oral iron Intravenous + oral iron 𝑃
(𝑁 = 150) (𝑁 = 75)
Maternal age at delivery (years) 32.1 (5.4) 31.5 (6.1) 0.46
Gestational age (weeks) 39.2 (2.9) 39.1 (3.0) 0.91
Gravidity 2.0 (1.4) 2.1 (1.6) 0.77
Parity 1.6 (0.9) 1.5 (1.1) 0.63
Blood loss, estimated (mL) 537.2 (283.5) 625.9 (404.9) 0.06
Hb after delivery (g/dL) 10.1 (0.3) [9.5–10.5] 9.1 (0.3) [8.5–9.5] <0.0001
Haematocrit after delivery (%) 29.5 (1.4) [25.4–36.2] 26.9 (1.7) [23–31.5] <0.0001
Mode of delivery
Vaginal spontaneous 54 (36%) 33 (44%)
Vaginal operative 28 (18.7%) 9 (12%)
Caesarean section 68 (45.3%) 33 (44%)
Values are expressed as mean (SD) [range], or numbers and percentages.
discharge for those with Hb 9.6–10.5 g/dL measured 24–48 h
post-partum (𝑛 = 150) or in the case of post-partum Hb
8.5–9.5 g/dL (𝑛 = 77) they had received a single infusion
of 500mg iron carboxymaltose (Ferinject) diluted in 100mL
sodium chloride 0.9% followed by the same prescription for
oral iron sulphate containing 80mg elemental iron/day.
Patients were questioned 6 months postpartum about
oral medication compliance, physical performance (con-
ventional Hayes and Paterson visual analogue scale (VAS)
from 1 to 10 comparable to a VAS for pain), diet (veg-
etarian/nonvegetarian), duration of breast-feeding, degree
of menstrual blood loss, and adverse events during intra-
venous and oral iron therapy. Exclusion criteria were surgery,
blood transfusion, and/or additional intravenous iron ther-
apy within the intervening 6 months.
2.1. Statistical Analysis. Groups were compared using the
Mann-Whitney test or Pearson’s chi-squared test where
appropriate. A 𝑃 value < 0.05 was used in all tests. Data are
given as the mean ± SD. Sample sizes were calculated by
power analysis (StatView 5.0.1, SAS Institute, Cary,NC,USA).
3. Results
3.1. Patient Characteristics. After reviewing the records of
1509 women with postpartum anaemia over a 26-month
period, we included 225 women in the study. Three women
were administered an additional dose of intravenous iron
postpartum and were therefore excluded. None underwent
surgery or received blood transfusions in the 6 months
postpartum. The remaining 1281 women either could not be
reached or decided not to participate. One hundred and fifty
women had postpartum Hb 9.6–10.5 g/dL and were assigned
to oral iron only; 75 women had postpartum Hb 8.5–9.5 g/dL
and received intravenous + oral iron.Maternal age at delivery,
gestational age at delivery, number of previous pregnancies,
and number of previous births did not differ significantly
between the two groups (Table 1).
3.2. Haematological Response (Table 2). At 6 months only
three and four women remained anaemic in the oral and
intravenous + oral groups. Mean Hb increased from 10.1 g/dL
postpartum to 13.3 ± 0.83 g/dL at 6 months versus from
9.1 g/dL to 13.3 ± 0.84 g/dL (𝑃 = 0.68). Of all the other haema-
tological parameters, only mean corpuscular haemoglobin
significantly differed statistically between the groups, being
higher in the intravenous + oral group (𝑃 < 0.05).
3.3. Iron Status and Inflammatory Response. Mean ferritin
at 6 months was statistically significantly lower in the oral
group: 32.9 ± 20.1𝜇g/L (range 4–111 𝜇g/L) versus 57.7 ±
49.3 𝜇g/L (range 9–296𝜇g/L) (𝑃 < 0.0001).
CRP levels were similar in both groups: 2.0 ± 4.4mg/L
versus 1.8 ± 2.7mg/L.
3.4. Questionnaire Results (Table 3). Self-reported durations
of oral iron supplementation ranged from 0 to 180 days across
groups, with a median of 46 days in the intravenous + oral
group and 30 days in the oral iron group, respectively; 52% of
patients in intravenous + oral group and 20% of patients in
the oral iron group took no oral treatment at all.
Therewere no statistical significant intergroup differences
in breast-feeding practice and duration, proportion of vege-
tarians, self-rated physical performance, or reported return of
menstruation at 6 months (71.6% in the oral iron group and
62.7% in the intravenous + oral group).
3.5. Adverse Events. No intravenous iron recipient could
recall any adverse effects, although one woman elected
not to participate due to persistent cutaneous infiltration
after injection-related extravasation. While the intravenous
administration was generally very well tolerated, the women
in the orally supplemented group frequently complained of
gastrointestinal symptoms, such as abdominal pain and
constipation.
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Table 2: Laboratory data 6 months post-partum.
Characteristics Oral iron Intravenous + oral iron 𝑃
(𝑁 = 150) (𝑁 = 75)
Hb (g/dL) 13.3 (0.8) [10.9–15.3] 13.3 (0.8) [11.1–15.7] 0.68
Haematocrit (%) 39.5 (2.3) [32.8–46.4] 39.4 (2.6) [34.1–47.6] 0.78
MCV (fL) 85.6 (4.4) [71.7–97.8] 86.6 (5.1) [72.7–97.7] 0.13
MCH (pg) 28.8 (1.7) [22.5–32.1] 29.3 (1.9) [21.8–34] 0.047
MCHC (g/dL) 33.6 (1.0) [30.4–35.9] 33.8 (1.1) [30.0–37.3] 0.15
Microcytes (%) 1.5 (1.9) [0.1–13.2] 1.3 (2.1) [0.1–13.9] 0.48
Hypochromic erythrocytes (%) 1.7 (3.6) [0.1–24.9] 1.3 (3.0) [0.1–18.9] 0.43
Ferritin (𝜇g/L) 32.9 (20.1) [4–111] 57.7 (49.3) [9–296] <0.0001
CRP (mg/L) 2.0 (4.4) [0–39] 1.8 (2.7) [0–11] 0.69
Values are expressed as mean (SD) [range].
Table 3: Questionnaire data at 6 months post-partum.
Oral iron Intravenous + oral iron
𝑃
(𝑁 = 150) (𝑁 = 75)
Median duration of 80mg/d oral iron sulphate
supplementation (days) (all patients) 30 (46.8) [0–180] 46 (45.2) [0–180] .02
Women taking oral iron supplementation [𝑁 (%)] 120 (80%) 36 (48%) .006
Breast-feeding women [𝑁 (%)] 131 (87.3%)(mean 20.9 weeks)
68 (90.7%)
(mean 20.7 weeks) .84
Vegetarians [𝑁 (%)] 11 (7.4%) 8 (10.8%) .34
Mean physical performance (scale 1–10) 6.9 (1.9) [2–10] 7.2 (1.7) [2–10] .36
Menstruation 6 months post-partum
None 42 (28.4%) 28 (37.3%) .29
Yes 106 (71.6%) 47 (62.7%)
Values are expressed as mean (SD) [range], or numbers and percentages.
4. Discussion
Our results show that iron supplementation, whether oral
only or intravenous + oral, is an effective treatment of post-
partum anaemia. Women with initially more severe anaemia
treated with intravenous + oral iron reached the same Hb
level 6 months later as those prescribed oral iron for mild
anaemia. However, our data show that intravenous supple-
mentation is the more effective approach for long-term iron
store replenishment. Safety and tolerability studies of iron
carboxymaltose show infrequent side effects [14–16].
Previous studies found oral iron and intravenous iron
to be equieffective treatments for correcting postpartum
anaemic Hb levels up to the initial three months [9, 11].
The novelty of our study is that we measured laboratory
parameters at 6 months, thus giving a more accurate estimate
of long-term effect.
Despite being anaemic after delivery, all but seven
patients (four and three, resp.) had normal Hb levels at 6
months.The lowestHb at 6monthswas 10.9 g/dL.One patient
in the intravenous + oral group with an Hb of 11.2 g/dL
combined with a ferritin of 296𝜇g/L was referred to a
haematologist for a possible haemoglobinopathy.
Mean ferritin levels were statistically significantly higher
in the intravenous + oral group: although these women had
been more anaemic on starting treatment, their iron stores
were better restored half a year later. One reason might be
the well-documented problems associated with the intestinal
absorption of oral iron, including iron sulphate. Various
factors such as diet may impair oral iron uptake. Postpartum
serum ferritin levels were notmeasured given that ferritin can
be elevated as an acute-phase protein for at least the first two
weeks of the puerperium, thus showing no correlation with
iron stores [17].
Gastrointestinal side effects are a well-recognised con-
tributor to poor patient compliance with long-term oral iron
treatment [18]. Many of the women in our study who ended
oral iron supplementation shortly after discharge complained
of abdominal pain and constipation. Twenty percent in the
oral iron alone group and 52% of women in the intravenous
+ oral group did not even start oral treatment. One might
speculate that the statistical significant higher rate of non-
starters of oral iron in intravenous + oral group is based on a
lesser psychological strain after having had an iron infusion.
However, the remaining women who continued oral treat-
ment must be presumed to have done so, based on their self-
reported declarations, for considerably longer than the pre-
scribed 6 weeks (42 days) in order to have achieved a median
duration of oral iron supplementation of 46 days. The com-
pliance figures in these women were higher than expected,
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bearing in mind that they were not being regularly encour-
aged to take the tablets.
The fact that we administered the questionnaire retro-
spectively, 4.5 months after the nominal completion of the 6
week oral therapy, could account for inaccurate recollection.
We conclude from the apparent spread of self-reported
compliance data and the absence of any external compliance
monitoring that our data simply reflect the noninterventional
observational nature of our study. They are the findings to
be expected under real-life practice conditions, representing
actual outcomes in unobserved patients in contrast to data
obtained in studies of closely supervised patients.
Our findings are consistent with those of Bhandal and
Russell who showed that intravenous iron sucrose increases
Hb levels more rapidly and replenishes iron stores more
efficiently than oral iron sulphate [9]. On postpartum day 40
Hb levels in both their study groups were similar, but iron
reserves were significantly higher in the intravenous group.
Our study now shows that this difference remains statistically
significant for up to 6 months. However, in contrast to our
own population, the women in the Bhandal and Russell study
were all severely anaemic, with similarly low mean group Hb
levels on starting treatment (7.5 g/dL and 7.3 g/dL). We also
prescribed a lower dose of oral iron sulphate than Bhandal
and Russell in order to maintain tolerability while remaining
effective in restoring the depleted iron stores [19].
Given that postpartum injection of intravenous iron
carboxymaltose is more effective than oral alternatives in
replenishing iron resources, we would advocate its use as the
treatment of choice not only in moderately severe anaemia
but also in mild postpartum anaemia, in particular for
women planning a subsequent pregnancy. However, further
studies are needed to determine the precise impact of post-
partum anaemia therapy on a future pregnancy.
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